High-dose psilocybin shows promise for depression treatment

Depression News

High-dose psilocybin shows promise for depression treatment
AntidepressantEfficacyPlacebo
  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 40 sec. here
  • 6 min. at publisher
  • 📊 Quality Score:
  • News: 33%
  • Publisher: 71%

Researchers compare the effectiveness and acceptability of oral monotherapy with psychedelics for the treatment of depressive symptoms.

By Vijay Kumar MalesuReviewed by Benedette Cuffari, M.Sc.Aug 27 2024 Study: Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. Image Credit: YAR Photographer / Shutterstock.com

Further research is needed to accurately determine the true efficacy of psychedelics, as current trials may be biased by compromised blinding and the influence of psychological support. The authors independently conducted data extraction and risk of bias assessment, resolving any discrepancies through discussion. Bayesian network meta-analysis was used to estimate relative effects between interventions, with sensitivity analyses addressing potential effect-modifying factors.

Taken together, these studies comprised 15 trials involving 811 participants in psychedelic trials with an average age of 42.5 years, 54.2% of whom were women. Additionally, 1,968 participants were involved in escitalopram trials, whose average age was 39.4 years, 62.5% of whom were women.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NewsMedical /  🏆 19. in UK

Antidepressant Efficacy Placebo Research

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Researchers discover rare sequence variants that associate with a high risk of Parkinson's diseaseResearchers discover rare sequence variants that associate with a high risk of Parkinson's diseaseScientists at deCODE genetics, a subsidiary of AMGEN, have discovered rare sequence variants, predicted to cause a loss of function of ITSN1, that are associated with a high risk of Parkinson's disease. The findings also support less studied pathways involved in the pathogenesis of the disease.
Read more »

Researchers identify malignant cells responsible for relapse in high-risk neuroblastomaResearchers identify malignant cells responsible for relapse in high-risk neuroblastomaResearchers at Children's Hospital of Philadelphia (CHOP) announced a significant breakthrough in understanding chemotherapy resistance in high-risk neuroblastoma, a common and potentially deadly childhood cancer arising within the peripheral nervous system.
Read more »

Toilet wars: the race for the quietest flushToilet wars: the race for the quietest flushInside the fiercely competitive, high-tech, high-ticket world of beyond-bog-standard loos
Read more »

Researchers develop affordable, rapid blood test for brain cancerResearchers develop affordable, rapid blood test for brain cancerResearchers at the University of Notre Dame have developed a novel, automated device capable of diagnosing glioblastoma, a fast-growing and incurable brain cancer, in less than an hour. The average glioblastoma patient survives 12–18 months after diagnosis.
Read more »

Roads not more dangerous when cyclists allowed to roll through stop signs, researchers suggestRoads not more dangerous when cyclists allowed to roll through stop signs, researchers suggestCyclists rolling through stop signs isn't safety risk
Read more »

Researchers identify immune profile for lung disease caused by allergic reactionResearchers identify immune profile for lung disease caused by allergic reactionFibrotic hypersensitivity pneumonitis is a chronic and progressive interstitial lung disease, caused by an immune response to inhaled foreign antigens or allergens.
Read more »



Render Time: 2025-02-15 11:39:05